% | $
Quotes you view appear here for quick access.

Exelixis, Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • wilderguide wilderguide Mar 30, 2012 5:59 PM Flag

    AACR Annual Meeting - Mar 31- Apr 4


    Hi Clem,

    Maybe I'm looking at this mistakenly, but my impressions of proven CABO compatibility with established therapies can only add to it's commercial value.

    Compatibility w/o adverse effect would be a hit, but any indication of metabolic synergy with either abiraterone or docetaxel (or both) would be a grand slam. I would think we'd see a commensurate upward valuation of EXEL if these therapies prove effective...and an outright skyrocket if synergy is pronounced.

    Why JNJ as a likely buyor? Why not?
    I would think they'd be on the lookout if only for the bone mets effect. It'd put them into a lot of markets in which they currently have no presence. But, I mention them only because of the recently announced Abby combo trial. Once enrolled & moving, I think this trial will amongst the most watched in the industry.

5.36-0.13(-2.37%)11:34 AMEST